The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | MDS & AML highlights from EHA 2026: secondary myeloid malignancies after CAR-T & menin inhibitors
In this video, Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, comments on two notable topics in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) from EHA 2026, including the development of secondary myeloid malignancies post CAR T-cell therapy and the potential of menin inhibitors in treating these malignancies. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
